Published in Br Med J (Clin Res Ed) on June 11, 1988
Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci U S A (1990) 2.72
Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res (2004) 2.33
Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat (2008) 1.41
Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1. J Cell Biol (1992) 1.30
Expression of transforming growth factor beta mRNA isoforms in human breast cancer. Br J Cancer (1994) 1.13
Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer (1994) 1.09
Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer. Br J Cancer (1991) 1.04
Transcripts for transforming growth factors in human breast cancer: clinical correlates. Br J Cancer (1990) 1.02
Transforming growth factor-alpha promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells. Am J Pathol (1995) 0.95
Metastatic breast carcinoma of the coracoid process: two case reports. J Orthop Surg Res (2010) 0.95
Epidermal growth factor receptor and oestrogen receptors in the non-malignant part of the cancerous breast. Br J Cancer (1989) 0.94
Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Res (2012) 0.94
Isolation of a lactoferrin cDNA clone and its expression in human breast cancer. Br J Cancer (1992) 0.92
Transforming growth factor beta1 (TGF-beta1) is a preoperative prognostic indicator in advanced gastric carcinoma. Br J Cancer (1998) 0.91
TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin Exp Metastasis (2000) 0.91
Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. Br J Cancer (1995) 0.85
Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy. Br J Cancer (1996) 0.85
Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer (2000) 0.85
Developmental regulation of mammary-derived growth inhibitor expression in bovine mammary tissue. J Cell Biol (1990) 0.84
Gene expression in oestrogen-dependent human breast cancer xenograft tumours. Br J Cancer (1990) 0.83
Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer (1994) 0.82
Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions. J Virol (1996) 0.82
Stage-related plasma values of transforming growth factor-beta1 are steroid receptors dependent. Clin Exp Med (2009) 0.77
Effect of human recombinant tumour necrosis factor and rat gamma interferon on nitrosomethylurea-induced mammary tumours. Br J Cancer (1989) 0.77
Stromal PDGFR-α Activation Enhances Matrix Stiffness, Impedes Mammary Ductal Development, and Accelerates Tumor Growth. Neoplasia (2017) 0.75
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry (1979) 180.95
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci U S A (1980) 109.70
Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose. Proc Natl Acad Sci U S A (1972) 83.88
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature (1985) 10.13
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Human transforming growth factor-alpha: precursor structure and expression in E. coli. Cell (1984) 5.39
cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines. Nature (1986) 4.81
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res (1987) 4.44
Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet (1987) 4.28
Growth factors and cancer. Cancer Res (1986) 3.48
Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell (1987) 3.45
A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem (1982) 3.04
Insulin-like growth factor II precursor gene organization in relation to insulin gene family. Nature (1984) 2.53
Chromosomal localization of the human homolog (c-sis) of the simian sarcoma virus onc gene. Science (1982) 2.27
A partially purified polypeptide fraction from rat liver cell conditioned medium with multiplication-stimulating activity for embryo fibroblasts. J Cell Physiol (1973) 1.93
Improved sensitivity in the measurement of estrogen receptor in human breast cancer. J Clin Endocrinol Metab (1973) 1.51
Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res (1984) 1.45
Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res (1986) 1.44
Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res (1984) 1.40
Frequent expression of growth factors for mesenchymal cells in human mammary carcinoma cell lines. Cancer Res (1987) 1.35
Production of PDGF-like growth factor by breast cancer cell lines. Int J Cancer (1985) 1.23
Epidermal growth factor receptors in human breast cancer. Breast Cancer Res Treat (1984) 1.21
Presence of transforming growth factors in human breast cancer cells. Cancer Res (1984) 1.21
8th San Antonio Breast Cancer Symposium--Plenary lecture. Autocrine and paracrine growth regulation of human breast cancer. Breast Cancer Res Treat (1986) 1.11
Receptor binding and growth-promoting activity of insulin-like growth factors in human breast cancer cells (T-47D) in culture. Cancer Res (1984) 0.93
Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 9.78
The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet (2008) 6.50
A world without mangroves? Science (2007) 6.13
Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet (1994) 4.03
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia (2002) 3.90
Bone disease after jejuno-ileal bypass for obesity. Lancet (1978) 3.84
The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol (2008) 3.31
Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet (1980) 2.82
The use of antisera to epithelial membrane antigen in detecting micrometastases in histological sections. Br J Cancer (1980) 2.50
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol (1993) 2.50
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Plasma-immunoreactive-calcitonin in patients with non-thyroid tumours. Lancet (1974) 2.30
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat (2001) 2.26
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res (2001) 2.15
Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer (1992) 2.10
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Detection of micrometastases in patients with primary breast cancer. Lancet (1983) 2.07
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res (2001) 2.06
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (2015) 2.05
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res (1987) 2.03
Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin. Lancet (1976) 1.92
Assessment of biochemical tests to screen for metastases in patients with breast cancer. Lancet (1980) 1.88
Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res (1994) 1.84
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer (1973) 1.81
Survey of treatment of primary breast cancer in Great Britain. Br Med J (Clin Res Ed) (1985) 1.80
Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia (2000) 1.79
Vitamin D status and bone histomorphometry in gross obesity. Am J Clin Nutr (1981) 1.79
Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell (2000) 1.77
Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer (1983) 1.73
Diagnosing breast carcinoma in young women. BMJ (1991) 1.71
Tamoxifen for the prevention of breast cancer. Eur J Cancer (2000) 1.62
Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol (1999) 1.60
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol (2005) 1.59
Effect of antilymphocyte serum on the growth of Hep 2 and HeLa cells in mice. Nature (1968) 1.58
Treatment of gross obesity by jejunal bypass. Br Med J (1974) 1.55
Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A (2001) 1.55
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia (1999) 1.55
Intramedullary pressure and bone marrow fat extravasation in reamed and unreamed femoral nailing. J Orthop Res (1999) 1.53
Topical calcipotriol treatment in advanced breast cancer. Lancet (1991) 1.53
Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Ann Oncol (1999) 1.51
Estrogen and progesterone receptors in the normal female breast. Cancer Res (1991) 1.50
Biocomplexity in mangrove ecosystems. Ann Rev Mar Sci (2010) 1.48
Biochemical markers in human breast cancer. Lancet (1977) 1.48
c-erbB-2 expression in benign and malignant breast disease. Br J Cancer (1988) 1.47
Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet (1987) 1.46
Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer (2000) 1.45
Clinical examination, xeromammography, and fine-needle aspiration cytology in diagnosis of breast tumours. Br Med J (1978) 1.44
Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem (1997) 1.42
Physical test for distant metastases in patients with breast cancer. J R Soc Med (1980) 1.42
Estrogen receptor beta in breast cancer. Endocr Relat Cancer (2002) 1.41
Prevention of breast cancer. Curr Opin Oncol (1991) 1.39
Technique for abdominal radical total gastrectomy. Br J Surg (1989) 1.39
Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer (1981) 1.39
Reversal of jejunoileal bypass in patients with morbid obesity. Br J Surg (1994) 1.39
Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. J Clin Oncol (1986) 1.39
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer (2009) 1.38
Explanations for weight loss after ileojejunal bypass in gross obesity. Br Med J (1976) 1.37
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia (2003) 1.37
Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases. Br Med J (Clin Res Ed) (1987) 1.36
Transplantation of primary explants of human tumour to mice treated with antilymphocyte serum. Br J Cancer (1970) 1.36
Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet (1989) 1.36
4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet (1984) 1.35
FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene (2010) 1.34
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer (2008) 1.34
Tamoxifen and benign breast problems. Lancet (1987) 1.33